El interés en corto de Turnstone Biologics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Turnstone Biologics. Los datos de interés en corto se actualizan cada dos semanas.

Turnstone Biologics (NASDAQ:TSBX) Bolsa, Informe de interés en corto

Turnstone Biologics

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Turnstone Biologics Corp

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Otis Worldwide Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>)</h3>
<ul class="wp-block-list">
<li>On July 23, Otis lowered its FY25 sales guidance. &#8220;Otis delivered solid performance led by the strength of our Service segment that continues our steady growth trajectory, and contributed mid-single digit organic sales growth and both year over year and sequential operating profit margin expansion. Our industry leading maintenance portfolio grew 4% again this quarter,&#8221; said Chair, CEO &amp; President Judy Marks. The company's stock fell around 11% over the past five days and has a 52-week low of $86.00.</li>
<li>RSI Value: 27.8</li>
<li>OTIS Price Action: Shares of Otis Worldwide fell 2.1% to close at $87.90 on Monday.</li>
<li>Edge Stock Ratings: 31.68 Momentum score with Value at 26.88.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/otis"><img loading="lazy" decoding="async" width="403" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29073953/image-444.png" alt="" class="wp-image-1005029" style="width:334px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29073953/image-444.png 403w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29073953/image-444-300x135.png 300w" sizes="(max-width: 403px) 100vw, 403px" /></a></figure>
<h3 class="wp-block-heading">Lucas GC Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>)</h3>
<ul class="wp-block-list">
<li>On July 22, Lucas GC regained Nasdaq compliance with minimum bid price requirement. The company's stock fell around 45% over the past five days and <a href="https://www.benzinga.com/quote/LGCL">has a 52-week low </a>of $0.28.</li>
<li>RSI Value: 17</li>
<li>LGCL Price Action: Shares of Lucas GC fell 27.2% to close at $0.60 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in LGCL <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0729">stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0729"><img loading="lazy" decoding="async" width="921" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29074113/image-445.png" alt="" class="wp-image-1005034" style="width:625px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29074113/image-445.png 921w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29074113/image-445-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29074113/image-445-768x696.png 768w" sizes="(max-width: 921px) 100vw, 921px" /></a></figure>
<h3 class="wp-block-heading">ChargePoint Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>)</h3>
<ul class="wp-block-list">
<li>On July 28, the company announced a 1-for-20 reverse stock split.. The company's stock fell around 30% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/CHPT">low of $8.55.</a></li>
<li>RSI Value: 21.4</li>
<li>CHPT Ltd Price Action: Shares of ChargePoint fell 18.8% to close at $9.91 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0729">CHPT shares</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0729"><img loading="lazy" decoding="async" width="905" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29074229/image-446.png" alt="" class="wp-image-1005039" style="width:635px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29074229/image-446.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29074229/image-446-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29074229/image-446-768x705.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46656981/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

CHPT

LGCL

OTIS

Top 3 Industrials Stocks You'll Regret Missing In Q3

Piper Sandler analyst Anna Andreeva maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Neutral and lowers the price target from $270 to $200.

Price Target

Analyst Ratings

LULU

Piper Sandler Maintains Neutral on Lululemon Athletica, Lowers Price Target to $200

WIIM

GeneDx shares are trading higher after the company raised FY25 sales guidance above estimates.

Piper Sandler analyst Allison Bratzel maintains Abivax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVX#NASDAQ">ABVX</a>) with a Overweight and raises the price target from $70 to $112.

ABVX

Piper Sandler Maintains Overweight on Abivax, Raises Price Target to $112

Globe Life shares are trading lower after announcing the DOJ closed its investigation and will not take enforcement action.

Atlas Energy Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) ("Atlas" or the "Company") today announced the acquisition of Propflow, LLC ("PropFlow"), a leading provider of patented on-wellsite proppant filtration technology. The transaction, which closed on July 28, 2025, is intended to strengthen Atlas' existing proppant handling capabilities as part of the Company's vision of mine-to-blender proppant logistics. PropFlow provides a cutting-edge on-wellsite proppant filtration system that eliminates proppant debris at the wellsite, reducing frac equipment maintenance costs and downtime and aiding in 24/7 pumping operations.

AESI

Atlas Energy Buys PropFlow To Cut Frac Downtime And Boost 24/7 Pumping Efficiency

Financial update
The following is a summary of the Appendix 4C Cash Flow Report:
<ul>
<li>The year-end closing cash balance was $29.12 million, a rise from $18.58 million at the close of the previous year.</li>
<li>Net cash outflows from operating activities for the year totaled $36.67 million. Direct Research and Development expenditure and Staff Costs comprised over 90% of the total operating expenditure for the year and quarter.</li>
<li>On July 16, 2025, the Company reported the receipt of $4.58 million for the research and development tax incentive and associated interest for the 2024 financial year.</li>
</ul>

Earnings

RADX

Radiopharm Theranostics Reported FY25 Cash Balance Of $29.12M, Operating Cash Flow Of $36.67M, Confirmed Guidance of Cash Runway Through To Mid-2026

<ul>
<li>Ermenegildo Zegna Group and Temasek signed a share purchase and investor rights agreement under which the Italian Group will sell 14.1m in the Company's treasury shares to the Singapore-headquartered investment company at a price of $8.95 per share</li>
<li>Upon closing, Temasek will hold, in total, 26.8m shares, equal to 10% of Ermenegildo Zegna Group's ordinary shares outstanding, having previously acquired 12.7m shares on the market</li>
<li>At the completion of the purchase, the Ermenegildo Zegna Group will receive $126.4m in cash</li>
<li>Nagi Hamiyeh, Head of EMEA of Temasek, is expected to become a non-executive member of the Board of Directors at its next annual General Meeting</li>
<li>The transaction affirms the strength of the Ermenegildo Zegna Group's vision and enhances its financial flexibility to support the organic growth of its current brands' portfolio</li>
</ul>
Ermenegildo Zegna N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZGN#NYSE">ZGN</a>) (the "Company" and, together with its consolidated subsidiaries, the "Ermenegildo Zegna Group" or the "Group") and Venezio Investments Pte. Ltd., an indirect wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek") today announced an agreement under which the Singapore-headquartered investment company will invest in the Italian luxury Group. Temasek has agreed to purchase 14,121,062 in the Company treasury shares, at a price of $8.95 per share (the "Transaction"), in line with the volume-weighted average of ZGN shares' prices over the period from June 30 to July 25, 2025. Temasek has previously acquired 12,699,981 ordinary shares of the Company through market purchases which, together with the shares to be acquired in the Transaction, will represent a 10% stake in the Company's ordinary share capital outstanding after conclusion of the Transaction.

Temasek Agrees To Purchase Over 14.1M In Ermenegildo Zegna Treasury Shares, At Price Of $8.95/Shr

Boeing Says 737 Production Reached 38/Month In Q2

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

ZOOZ

ZOOZ Announces $180M Private Placement For Bitcoin Treasury Strategy

- Zervimesine's impact on debilitating DLB behavioral symptoms highlighted in podium presentation - - Plasma p-tau217 levels can identify Alzheimer's patients most likely to benefit from zervimesine treatment - - Plasma and CSF biomarkers support zervimesine's impact on Alzheimer's disease biology -
PURCHASE, N.Y., July 29, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=6J0YotdkLWh3dSvCt4YGgYtoTcoLQ595-2aqH8SRqgKUmvwhRmdq5qxqaV9xqfZ4reOBrqsIiaAkm2WMWAPqrwsHjF6OXgVSrcSIme5OgSlOitmtvEyiyomjNPAlfent">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>), a clinical stage company developing drugs that treat neurodegenerative disorders, presented results from the Phase 2 COG1201 SHIMMER study (<a href="https://www.globenewswire.com/Tracker?data=Z47E-K0OvP2AbBNC7tywecR0jgocwWJS7hv3sVTJkmIeQ0gH_GPuwTYhtqvOrpw1kMtmqsOUWA6e7TSkBbZtaJ3Rv38YlQ51FXw6sc3m6RYCOW2ckKoqacL25N4AyGyN">NCT05225415</a>) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the Alzheimer's Association International Conference (AAIC 2025).
As previously reported, the SHIMMER study met its primary endpoint of safety and tolerability. Results showed that zervimesine treatment had a positive impact across neuropsychiatric, cognitive, motor, and functional scales. After six months of treatment, DLB patients treated with zervimesine scored an average of 86% better than placebo-treated patients on the neuropsychiatric inventory (NPI-12). This tool measures 12 separate behavioral symptoms, including hallucinations, delusions, and anxiety, which are hallmarks of DLB. The findings were presented by James E. Galvin, MD, MPH during a Featured Research Session on July 29, 2025.

CGTX

Cognition Therapeutics Presents Results From Phase 2 COG1201 SHIMMER Study Of Zervimesine In Dementia With Lewy Bodies At AAIC 2025

<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/29101358/ChatGPT-Image-Jul-29-2025-at-12_13_07-PM-1024x683.png" alt="" class="wp-image-16563" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/29101358/ChatGPT-Image-Jul-29-2025-at-12_13_07-PM-1024x683.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/29101358/ChatGPT-Image-Jul-29-2025-at-12_13_07-PM-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/29101358/ChatGPT-Image-Jul-29-2025-at-12_13_07-PM-768x512.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/29101358/ChatGPT-Image-Jul-29-2025-at-12_13_07-PM.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Image generated by AI.
A wager, a trade, a contract – can you tell the difference? Each one involves a calculated risk predicated on a hoped-for outcome. Prediction markets blur the boundary further.
Even before Polymarket&nbsp;<a href="https://ballotpedia.org/Prediction_markets_in_the_2024_presidential_election" target="_blank" rel="noreferrer noopener">correctly called the winner of last year's US presidential election</a> the line was pretty fuzzy. Then <a href="https://www.techopedia.com/definition/30246/blockchain">blockchain technology</a> bridged it. When the <a href="https://www.nbcnews.com/politics/2024-election/election-betting-newly-legal-risks-getting-confused-polls-rcna177880" target="_blank" rel="noreferrer noopener">ban</a>&nbsp;on political betting was lifted in 2024, a door was opened. Prediction market platforms walked straight through.
Last month the category minted its first unicorns. Polymarket raised $200 million on a $1 billion valuation. Two days later, Kalshi announced a $185 million round against a whopping $2 billion price tag.
With online trading giants like&nbsp;<a href="https://newsroom.aboutrobinhood.com/robinhood-prediction-markets-hub/" target="_blank" rel="noreferrer noopener">Robinhood getting into the game</a>, investors see big things in store. Have prediction markets achieved liftoff? And what about the blockchain upstarts who hope to exploit the leaders&#8217; Achilles Heel?
<h1 class="wp-block-heading">Hedging the future</h1>
Prediction markets let anyone try their hand at forecasting the future and get paid when they get it right. Everyone from sports fans to current affairs buffs can channel their inner Nostradamus and take a punt on topics both trivial and weighty – perhaps the&nbsp;<a href="https://kalshi.com/markets/kxrtsuperman/superman-rotten-tomatoes-score" target="_blank" rel="noreferrer noopener">likely Rotten Tomatoes score</a>&nbsp;for the next Superman movie, or who will be New York City's <a href="https://kalshi.com/markets/kxmayornycparty/mayor-of-nyc-party-winner">next mayor</a>. 
For economists and others who try to tap into&nbsp;<a href="https://hbr.org/2018/12/the-right-way-to-use-the-wisdom-of-crowds" target="_blank" rel="noreferrer noopener">the wisdom of crowds</a>, the success of prediction market platforms makes perfect sense. They offer a future where every uncertainty can be priced, hedged, and insured against.
They're built on the idea that a large pool of bettors with cash on the line can foresee an outcome better than any one expert, no matter how deep their expertise. The risk of losing money switches on a collective power of premonition, the thinking goes. The right algorithm can bring it to the surface. 
For end users, prediction market platforms make participation easy.
<ul class="wp-block-list">
<li>Create an account&nbsp;and log in, select the event they want to bet on, and decide the size of their wager.</li>
<li>Buy a share&nbsp;of an event contract, which is tied to a particular outcome (e.g., ‘this will be / won't be the hottest July ever').</li>
<li>Wait for the final outcome. Shares trade for between a penny and a dollar. Once the final outcome is known, those who chose correctly get a payout for each share.</li>
</ul>
If you buy a share for 48 cents, predicting that this July will be the hottest on record – and the prediction comes true – you make 52 cents on the dollar. The final payout depends on the number of correct-outcome shares you purchased.
<h1 class="wp-block-heading">A New DeFi Growth Opportunity?</h1>
How attractive is that as a proposition?&nbsp;<a href="https://dune.com/rchen8/polymarket" target="_blank" rel="noreferrer noopener">Figures from Dune Analytics</a>&nbsp;show that monthly volume, active users, and new account signups on Polymarket all spiked in the runup to the 2024 US election, but then settled back.
Min Jung, an analyst at Presto Research, believes that&nbsp;<a href="https://www.prestolabs.io/research/prediction-markets-the-next-big-thing" target="_blank" rel="noreferrer noopener">prediction markets show promise</a>&nbsp;but suffer from a&nbsp;liquidity problem. 
"Even at their peak, attention has been mostly short-lived and limited to certain periods like elections, with only the top three to five markets having enough volume for people to trade in size (e.g., $1000)."
Another issue can be the time it takes for a prediction market event to resolve. In sports, you know an event outcome within a few days. For some prediction events, users don't know exactly when the resolution will happen or if it will occur before the event contract's end date.
Prediction markets will struggle to attract and keep these zero days to expiration (0DTE) users, Jung added, "as they prefer quick resolutions."
And of course, the&nbsp;<a href="https://x.com/michael_lwy/status/1877211555496079683" target="_blank" rel="noreferrer noopener">algorithmic truth-telling they rely on isn't infallible</a>. A 2024 event contract on the likelihood of a US government shutdown caused an uproar when it resolved to a 'yes' (meaning a shutdown will happen) even after the federal budget bill gained assent and ‘no shutdown' was confirmed.
<h1 class="wp-block-heading">Predicting upstarts</h1>
Another issue that could stymie the category's growth is a lack of freedom and flexibility. On Kalshi and Polymarket the platforms gate-keep the events worth predicting. End users shop from a list of pre-set event contracts and select the one that interests them most.
New entrants want to let users decide what's worth a wager.
Prediction market startup&nbsp;<a href="https://xo.market/" target="_blank" rel="noreferrer noopener">XO Market</a>&nbsp;sees an opportunity to leverage dissatisfaction by making its system AI-driven. Instead of relying on humans, XO's oracle uses&nbsp;data analytics&nbsp;and&nbsp;machine learning&nbsp;to quickly calculate outcomes transparently and verifiably.
If a conflict does arise, XO has its own dispute panel, though it's composed of staked XO token holders who are chosen by a randomizing algorithm to vote on a resolution. A quadratic voting mechanism is also applied to minimize the influence of any one large token holder.
XO Market also aims to be&nbsp;permissionless, which would set it apart from Polymarket and Kalshi, where event contracts are approved by human arbitration. XO would allow end users more power to shape new markets by drafting questions for new event contracts and helping define resolution criteria.
<h1 class="wp-block-heading">The take away</h1>
Bookies have long been known to be better&nbsp;<a href="https://users.wfu.edu/strumpks/papers/BettingPaper_final(JEP_Resubmit).pdf" target="_blank" rel="noreferrer noopener">predictors of political contests</a>&nbsp;than traditional pollsters, yet mainstream media treat psephologists as oracles while bookies' odds get tacked on to election news as colorful footnotes.
Now that their mathematical reliability is better understood, prediction markets are turning betting into an attractive pastime – very attractive, as recent valuations attest.
From stock markets to fantasy sports leagues, a significant number of people devote loads of time, effort, money, and brainpower to working out what comes next. Prediction markets trade on this very human propensity and democratize it to a wider spectrum.
Decentralized, blockchain-based platforms promise a more trusted and insight-driven betting environment. They can also deliver big money. The infamous Polymarket whale who went all-in on a Trump White House win received an estimated payout of around&nbsp;<a href="https://finance.yahoo.com/news/polymarket-whale-actually-made-85-050139914.html" target="_blank" rel="noreferrer noopener">$85 million</a>. Who would have foreseen that?

Opinion

Tech

General

Prediction Markets Hit Fever Pitch

BMO Capital analyst Michael Zaremski maintains Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) with a Market Perform and raises the price target from $429 to $474.

KNSL

BMO Capital Maintains Market Perform on Kinsale Cap Gr, Raises Price Target to $474

MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>), a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Ketamir-2, a novel oral NMDA receptor antagonist for the treatment of neuropathic pain.
The IND submission included a comprehensive data package encompassing preclinical pharmacology, safety, and toxicology studies, including a pivotal neurotoxicity study in Sprague-Dawley rats which showed no evidence of brain lesions or adverse CNS effects-a key distinction from traditional ketamine, which has been associated with NMDA-linked neurotoxicity and the formation of Olney lesions in similar preclinical models. These findings were reinforced by multiple validated neuropathic pain models-including chemotherapy-induced, diabetic, and nerve ligation-induced neuropathy-where Ketamir-2 consistently demonstrated potent analgesic effects and superior efficacy to gabapentin and pregabalin, with reversal of pain sensitivity observed in select models. The IND also incorporated the Company's Phase 1 readiness data and manufacturing documentation.
MIRA is nearing completion of the Single Ascending Dose (SAD) portion of its international Phase 1 trial at Hadassah Medical Center in Jerusalem, with dose escalation progressing smoothly. The Company is now preparing to initiate the Multiple Ascending Dose (MAD) portion of the study, which will assess the safety, tolerability, and pharmacokinetics of repeated dosing over several days. These data will help inform optimal dosing strategies as MIRA moves toward a Phase 2a study, with the goal of initiating its first U.S.-based efficacy trial in Q4 2025.

Government

Regulations

MIRA

MIRA Pharma Gets FDA Green Light For Next-Gen Ketamine Alternative In Neuropathic Pain Trial

BMO Capital analyst John McNulty maintains Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) with a Market Perform and raises the price target from $52 to $67.

BMO Capital Maintains Market Perform on Hexcel, Raises Price Target to $67

Dragonfly Energy Holdings Corp. ("Dragonfly Energy" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>), an industry leader in energy storage and battery technology, today announced preliminary second quarter 2025 Net Sales and Adjusted EBITDA.
The Company anticipates second quarter 2025 Net Sales of $16.2&nbsp;million and Adjusted EBITDA of $(2.2) million, above guidance of $14.8 million and $(3.5) million, respectively. Anticipated results represent 23% year-over-year growth in Net Sales and an approximately $4 million reduction in Adjusted EBITDA loss.

DFLI

Dragonfly Energy Reported Preliminary Q2 Net Sales Of $16.2M, Up By 23% YoY,Topping Guidance Of $14.8M

Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) Flowserve Total sales growth for 2025 FY is expected to up by 5 to 6% YoY and Organic sales growth of 3 to 4% YoY

Guidance

Flowserve Total sales growth for 2025 FY is expected to up by 5 to 6% YoY and Organic sales growth of 3 to 4% YoY

BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW, BCTXZ))), (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), are pleased to announce that BriaPro is developing novel multivalent agents for cancer treatment. BriaPro has filed a provisional patent application for the underlying platform referred to as "TILsRx".
The TILsRx platform enables simultaneous engagement of multiple tumor-associated and immune pathway targets. Multivalent agents (including antibodies, soluble receptors and cytokines) address immune suppression and T cell exhaustion often seen with tumor-infiltrating lymphocytes (TILs) and aim to improve T cell activation and persistence in the tumor microenvironment. Designed to activate TILs and enhance TIL binding to tumor cells as well as block immune checkpoints that suppress anti-tumor responses, TILsRx agents are multifunctional in their cancer killing actions. Specific elements in TILsRx agents include soluble CD80, which has a dual function as an immune checkpoint inhibitor and as an immunostimulator, anti-CD3, which is a potent T cell activator, IL-21, which is an enhancer of cytotoxic T cell function, and anti-STEAP1 (STEAP1 is a cancer antigen expressed in prostate cancer among others). An early candidate target is B7-H3, a tumor antigen which is overexpressed in prostate, lung, breast, pancreatic, and ovarian cancer while minimally expressed in normal tissue.

BCTX

TSX:BCT

BriaCell Unveils TILsRx Platform Aiming To Supercharge Immune Response Against Hard-To-Treat Cancers

Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) reported quarterly losses of $(1.24) per share which missed the analyst consensus estimate of $(0.94) by 31.91 percent. This is a 57.24 percent increase over losses of $(2.90) per share from the same period last year. The company reported quarterly sales of $22.75 billion which beat the analyst consensus estimate of $20.20 billion by 12.64 percent. This is a 34.88 percent increase over sales of $16.87 billion the same period last year.

Earnings Beats

Earnings Misses

Boeing Q2 Adj. EPS $(1.24) Misses $(0.94) Estimate, Sales $22.75B Beat $20.20B Estimate

Biotech

Health Care

KNSA

Kiniksa Pharmaceuticals' ARCALYST 2025 Expected Net product Revenue Guidance Increased To $625M-$640M Compared To Prior Guidance Of $590M-$605M

Press Releases

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Comments

Turnstone Biologics

Interés en corto

Turnstone Biologics (NASDAQ:TSBX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL